ArticleDiscover oncology2025
Five cases report and literature review of malignant peripheral nerve sheath tumor.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleMalignant Peripheral Nerve Sheath Tumor (MPNST) is an aggressive soft tissue sarcoma with limited therapeutic options and a poor prognosis. Its occurrence is closely related to genetic factors, and it is associated with Neurofibromatosis type I (NF1) in about 50% of cases. The overall incidence ranges from 3% to 10%, and it has been on the rise in recent years.
methodsRetrospectively analyze the age of onset, tumor site, tumor size, metastasis, treatment plan, and prognosis of MPNST patients admitted to The First Affiliated Hospital of Henan Medical University from January 2018 to January 2022.
resultsIn the past 5 years, 5 patients with MPNST aged 20-64 years were admitted to our center, including 2 males and 3 females. As of our writing of this manuscript: Of the 4 patients who underwent surgery, Case 1 patient died due to severe complications with overall survival of 11 months, Cases 2 and 4 patients are still alive with overall survival of 68 and 42 months, respectively, Case 5 patient with combined NF1 with overall survival of 18 months, and the patient in Case 3 patient was found to be inoperable due to the evaluation of condition at the time of discovery, but survived after systemic treatment with an overall survival of 45 months. All surviving patients continue to be followed up.
conclusionWe described the clinical features, treatment, and clinical outcomes of 5 cases of MPNST, including one case of MPNST with NF1 gene mutation. This provides valuable clinical experience for the treatment of this rare tumor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.